Last reviewed · How we verify
CD123 targeted CAR-NK cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells) — Chongqing Precision Biotech Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD123 targeted CAR-NK cells TARGET | CD123 targeted CAR-NK cells | Chongqing Precision Biotech Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD123 targeted CAR-NK cells CI watch — RSS
- CD123 targeted CAR-NK cells CI watch — Atom
- CD123 targeted CAR-NK cells CI watch — JSON
- CD123 targeted CAR-NK cells alone — RSS
Cite this brief
Drug Landscape (2026). CD123 targeted CAR-NK cells — Competitive Intelligence Brief. https://druglandscape.com/ci/cd123-targeted-car-nk-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab